The present invention relates to inhibitors of histone deacetylases, in particular HDAC8, that are useful for the treatment of cancer and other diseases and disorders, as well as the synthesis and applications of said inhibitors.

The present invention relates to inhibitors of histone deacetylases, in particular HDAC8, that are useful for the treatment of cancer and other diseases and disorders, as well as the synthesis and applications of said inhibitors.

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:

##STR00001##

which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:

##STR00001##

which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

The present invention provides compounds of Formula (I):

##STR00001##

wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are biased agonists, or ?-Arrestin agonists of the angiotensin II receptor, which may be used as medicaments.

The present invention provides compounds of Formula (I):

##STR00001##

wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are biased agonists, or ?-Arrestin agonists of the angiotensin II receptor, which may be used as medicaments.

Provided is a heterocyclic compound that may have a GCN2 inhibitory action, and is expected to be useful for the prophylaxis or treatment of GCN2 associated diseases including cancer and the like. A compound represented by the formula (I):

##STR00001##

wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

The present invention relates to inhibitors of histone deacetylases, in particular HDAC8, that are useful for the treatment of cancer and other diseases and disorders, as well as the synthesis and applications of said inhibitors.

The present invention relates to inhibitors of histone deacetylases, in particular HDAC8, that are useful for the treatment of cancer and other diseases and disorders, as well as the synthesis and applications of said inhibitors.

The present invention provides compounds of Formula (I): ##STR00001##
wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are biased agonists, or ?-Arrestin agonists of the angiotensin II receptor, which may be used as medicaments.